Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer Is Back In The CTLA-4 Game Via Pact With OncoImmune

Executive Summary

Pfizer bought an option to license OncoImmune’s anti-CTLA-4 antibody ONC-392 five years after out-licensing its own internal candidate tremelimumab to AstraZeneca following a study failure.

Advertisement

Related Content

Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register